MiR-101: a potential therapeutic target of cancers

被引:0
|
作者
Wang, Cen-Zhu [1 ]
Deng, Fei [1 ]
Li, Hao [2 ]
Wang, Dan-Dan [1 ]
Zhang, Wei [1 ]
Ding, Li [1 ]
Tang, Jin-Hai [1 ]
机构
[1] Nanjing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Nanjing 210029, Jiangsu, Peoples R China
[2] Xuzhou Med Univ, Sch Clin Med, 209 Tongshan Rd, Xuzhou 221004, Jiangsu, Peoples R China
来源
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH | 2018年 / 10卷 / 11期
关键词
miR-101; cancers; biomarker; therapeutic targets; INHIBITS CELL-PROLIFERATION; GROWTH-FACTOR-C; LUNG-CANCER; OSTEOSARCOMA CELLS; TUMOR-SUPPRESSOR; INDUCED APOPTOSIS; DOWN-REGULATION; GASTRIC-CANCER; MICRORNA-101; INVASION;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
MicroRNAs (miRNAs) are small noncoding RNAs that could regulate gene expressions transcriptionally or post-transcriptionally through binding to 3' untranslated region (3' UTR) of target messenger RNAs (mRNAs), which were identified to be associated with tumorigenesis in various neoplasms. Among them, miR-101, encoded by two precursor transcripts (miR-101-1 and miR-101-2), was recognized to serve as a tumor suppressor via targeting critical oncogenes or anti-oncogenes. Additionally, studies have shown that miR-101 was participated in multiple cancer-related biological processes, including proliferation, apoptosis, angiogenesis, drug resistance, invasion and metastasis. In this review, we aim to summarize the function of miR-101 in different biological processes by figuring out the underlying target gene networks and explore its potential role as a biomarker in diverse neoplasms, which will provide a brand-new insight in molecular targeting cancer treatment.
引用
收藏
页码:3310 / 3321
页数:12
相关论文
共 50 条
  • [31] MiR-101 reverses the hypomethylation of the LMO3 promoter in glioma cells
    Liu, Xiaoping
    Lei, Qianqian
    Yu, Zhibin
    Xu, Gang
    Tang, Hailin
    Wang, Wei
    Wang, Zeyou
    Li, Guiyuan
    Wu, Minghua
    ONCOTARGET, 2015, 6 (10) : 7930 - 7943
  • [32] miR-124, a potential therapeutic target in colorectal cancer
    Qin, Zhen
    Liu, Xia
    ONCOTARGETS AND THERAPY, 2019, 12 : 749 - 751
  • [33] MiR-29a-3p: a potential biomarker and therapeutic target in colorectal cancer
    Mo, Wen-Yan
    Cao, Shi-Qiong
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (03) : 563 - 577
  • [34] miR-449a: a potential therapeutic agent for cancer
    He Yong-Ming
    Ji Ai-Jun
    Xu Xiao-Yue
    Lu Jian-Wei
    Yu Chen
    Chen Ye
    ANTI-CANCER DRUGS, 2017, 28 (10) : 1067 - 1078
  • [35] Cathepsin K: A Versatile Potential Biomarker and Therapeutic Target for Various Cancers
    Qian, Die
    He, Lisha
    Zhang, Qing
    Li, Wenqing
    Tang, Dandan
    Wu, Chunjie
    Yang, Fei
    Li, Ke
    Zhang, Hong
    CURRENT ONCOLOGY, 2022, 29 (08) : 5963 - 5987
  • [36] Thrombospondin-1 as a Potential Therapeutic Target: Multiple Roles in Cancers
    Wang, Pengfei
    Zeng, Zheng
    Lin, Caiji
    Wang, Jiali
    Xu, Wenwen
    Ma, Wenqing
    Xiang, Qian
    Liu, Huidi
    Liu, Shu-Lin
    CURRENT PHARMACEUTICAL DESIGN, 2020, 26 (18) : 2116 - 2136
  • [37] PKCα mediated induction of miR-101 in human hepatoma HepG2 cells
    Chiang, Chao-Wei
    Huang, Yi
    Leong, Ka-Wai
    Chen, Lih-Chyang
    Chen, Hua-Chien
    Chen, Shu-Jen
    Chou, Chen-Kung
    JOURNAL OF BIOMEDICAL SCIENCE, 2010, 17
  • [38] miR-101 Promotes Breast Cancer Cell Apoptosis by Targeting Janus Kinase 2
    Wang, Lu
    Li, Linqiang
    Guo, Rui
    Li, Xuelian
    Lu, Ying
    Guan, Xiaoxiang
    Gitau, Samuel Chege
    Wang, Leimin
    Xu, Chaoqian
    Yang, Baofeng
    Shan, Hongli
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2014, 34 (02) : 413 - 422
  • [39] miR-101 DNA Copy Loss is a Prominent Subtype Specific Event in Lung Cancer
    Thu, Kelsie L.
    Chari, Raj
    Lockwood, William W.
    Lam, Stephen
    Lam, Wan L.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (09) : 1594 - 1598
  • [40] Application of capsaicin as a potential new therapeutic drug in human cancers
    Zhang, Shengping
    Wang, Dian
    Huang, Jingying
    Hu, Yueming
    Xu, Yafei
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2020, 45 (01) : 16 - 28